Atovaquone

Atovaquone Glenmark 750 mg/5 ml oral suspension is indicated for:

Acute treatment of mild to moderate Pneumocystis pneumonia (PCP, caused by Pneumocystis jiroveci, formerly classified as P. 4).

Each ATOVAQUONE PROGUANIL (atovaquone and proguanil hydrochloride) Tablet contains 250 mg of atovaquone and 100 mg proguanil hydrochloride. The daily dose should be taken with food or a milky drink (to ensure maximum absorption) at the same time each day (see PRECAUTIONS, General).

In the event of vomiting within 1 hour of dosing a repeat dose should be taken. Should vomiting continue, alternative therapy should be considered or the patient’s parasitemia should be monitored. ATOVAQUONE PROGUANIL Tablets (adult strength) should preferably be swallowed whole.

Either tablet may be crushed and mixed with condensed milk just prior to administration for children who may have difficulty swallowing tablets. ). Prophylaxis should be continued daily throughout the stay and for 7 additional days after leaving the area of concern.

Dosage in Adults One ATOVAQUONE PROGUANIL Tablet (adult strength = 250 mg atovaquone and 100 mg proguanil hydrochloride) daily. Dosage in Children (see PRECAUTIONS, Use in Children, and CLINICAL PHARMACOLOGY, Special Populations, Pediatrics) The dosage for prevention of malaria in children is based upon body weight.

1 INDICATIONS AND USAGE Atovaquone oral suspension is a quinone antimicrobial drug indicated for: Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX).

1 ) Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. 3 ): Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] >45 mm Hg) with atovaquone oral suspension has not been studied.

The efficacy of atovaquone oral suspension in subjects who are failing therapy with TMP-SMX has also not been studied. 1 Prevention of Pneumocystis jirovecii Pneumonia Atovaquone oral suspension is indicated for the prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX).

2 Treatment of Mild-to-Moderate Pneumocystis jirovecii Pneumonia Atovaquone oral suspension is indicated for the acute oral treatment of mild-to-moderate PCP in adults and adolescents (aged 13 years and older) who cannot tolerate TMP-SMX.